dallas semaglutide gastric intestinal obstruction lawsuit stomach paralysis lawyer law firm in kentucky attorney semaglutide diarrhea louisiana kentucky semaglutide gastrointestinal obstruction Wegovy® Lawsuit-mvanhaasteren.nl kentucky semaglutide gi dallas glp-1 attorney semaglutide gastric

Semaglutide targets only the GLP-1 receptor and achieved 14.9% mean weight loss at 68 weeks in the STEP 1 trial

The first step on any ladder, and a gentle re-entry after a break

Lilly has reported strong Phase 3 results, including 28.3% average weight loss over 80 weeks at the highest studied dose in one obesity trial, but the drug still requires regulatory review

The FDA's approval process requires manufacturers to establish reporting systems for adverse events, conduct post-market safety checks, and maintain surveillance programs that track safety issues as millions use the medication

The prevalence of gastrointestinal adverse events underscores the importance of patient education before initiating semaglutide therapy, including strategies for minimizing discomfort and recognizing warning signs that merit medical attention